Altimmune(US:ALT) Newsfilterยท2025-03-06 12:30Core Insights - Altimmune, Inc. will host a virtual R&D Day on March 13, 2025, at 12:00 pm Eastern Time [1] - The event will feature presentations from Key Opinion Leaders (KOLs) discussing the scientific rationale and clinical data for pemvidutide, along with future development plans [2] - Pemvidutide is being developed as a dual receptor agonist for obesity, MASH, and other indications [4] Event Details - The virtual R&D Day will be accessible via the Altimmune website and a dedicated event link [3] - The upcoming topline data readout from the Phase 2b trial in MASH is expected in the second quarter of 2025 [2] Company Overview - Altimmune is focused on next-generation peptide-based therapeutics and is currently in late clinical stages of development [4] - Pemvidutide targets GLP-1 and glucagon receptors, indicating a novel approach to treating obesity and related conditions [4]